Prospective observational Study to explore the efficacy of Eribulin as 1st-line or 2nd-line chemotherapy in patients with HER2-negative hormone-resistant inoperable or recurrent metastatic breast cancer
Objectives
The purpose of this observational study is to investigate the efficacy of eribulin as the first or second line chemotherapy to prolong overall survival and to explore factors affecting the survival in patients with HER2-negative hormone-resistant inoperable or recurrent metastatic breast cancer who scheduled to receive the first or second line chemotherapy in clinical practice in Japan.
State
Examination Completed
Subjects
HER2-negative hormone-resistant inoperable or recurrent metastatic breast cancer
Endpoints
Overall survival (OS) of the first line chemotherapy from starting date of the first line chemotherapy until death from any cause
Trial Period
2015 - 2022/4
Lead Principal Investigator
Takeshi Kotake
Yuichiro Kikawa
Target Sample Size
360
Number of Sample Size
201
Regimen
-
Source of Funding
Eisai
Umin ID
Other
Institutions
Kobe City Medical Center General Hospital(Hyogo), Kyoto University Hospital(Kyoto), Japanese Red Cross Osaka Hospital(Osaka), Tenri Hospital(Nara), Kitano Hospital(Osaka), Japanese Red Cross Wakayama Medical Center(Wakayama)
